253 related articles for article (PubMed ID: 28439615)
1. WIP1 phosphatase as pharmacological target in cancer therapy.
Pecháčková S; Burdová K; Macurek L
J Mol Med (Berl); 2017 Jun; 95(6):589-599. PubMed ID: 28439615
[TBL] [Abstract][Full Text] [Related]
2. WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors.
Burdova K; Storchova R; Palek M; Macurek L
Cells; 2019 Oct; 8(10):. PubMed ID: 31619012
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3.
Pechackova S; Burdova K; Benada J; Kleiblova P; Jenikova G; Macurek L
Oncotarget; 2016 Mar; 7(12):14458-75. PubMed ID: 26883108
[TBL] [Abstract][Full Text] [Related]
4. Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy.
Clausse V; Goloudina AR; Uyanik B; Kochetkova EY; Richaud S; Fedorova OA; Hammann A; Bardou M; Barlev NA; Garrido C; Demidov ON
Cell Death Dis; 2016 Apr; 7(4):e2195. PubMed ID: 27077811
[TBL] [Abstract][Full Text] [Related]
5. A novel assay for screening WIP1 phosphatase substrates in nuclear extracts.
Storchova R; Burdova K; Palek M; Medema RH; Macurek L
FEBS J; 2021 Oct; 288(20):6035-6051. PubMed ID: 33982878
[TBL] [Abstract][Full Text] [Related]
6. Wip1 phosphatase: between p53 and MAPK kinases pathways.
Goloudina AR; Kochetkova EY; Pospelova TV; Demidov ON
Oncotarget; 2016 May; 7(21):31563-71. PubMed ID: 26883196
[TBL] [Abstract][Full Text] [Related]
7. The role of PPM1D in cancer and advances in studies of its inhibitors.
Deng W; Li J; Dorrah K; Jimenez-Tapia D; Arriaga B; Hao Q; Cao W; Gao Z; Vadgama J; Wu Y
Biomed Pharmacother; 2020 May; 125():109956. PubMed ID: 32006900
[TBL] [Abstract][Full Text] [Related]
8. A novel mathematical model of ATM/p53/NF- κB pathways points to the importance of the DDR switch-off mechanisms.
Jonak K; Kurpas M; Szoltysek K; Janus P; Abramowicz A; Puszynski K
BMC Syst Biol; 2016 Aug; 10(1):75. PubMed ID: 27526774
[TBL] [Abstract][Full Text] [Related]
9. Wip1: A candidate phosphatase for cancer diagnosis and treatment.
Oghabi Bakhshaiesh T; Majidzadeh-A K; Esmaeili R
DNA Repair (Amst); 2017 Jun; 54():63-66. PubMed ID: 28385459
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-16 feedback loop with p53 and Wip1 can regulate cell fate determination between apoptosis and senescence in DNA damage response.
Issler MVC; Mombach JCM
PLoS One; 2017; 12(10):e0185794. PubMed ID: 28968438
[TBL] [Abstract][Full Text] [Related]
11. p53-Independent expression of wild-type p53-induced phosphatase 1 (Wip1) in methylmethane sulfonate-treated cancer cell lines and human tumors.
Park JY; Song JY; Kim HM; Han HS; Seol HS; Jang SJ; Choi J
Int J Biochem Cell Biol; 2012 Jun; 44(6):896-904. PubMed ID: 22405851
[TBL] [Abstract][Full Text] [Related]
12. Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
Clausse V; Tao D; Debnath S; Fang Y; Tagad HD; Wang Y; Sun H; LeClair CA; Mazur SJ; Lane K; Shi ZD; Vasalatiy O; Eells R; Baker LK; Henderson MJ; Webb MR; Shen M; Hall MD; Appella E; Appella DH; Coussens NP
J Biol Chem; 2019 Nov; 294(46):17654-17668. PubMed ID: 31481464
[TBL] [Abstract][Full Text] [Related]
13. Clinical Significance of the Wild Type p53-Induced Phosphatase 1 Expression in Invasive Breast Cancer.
Inoue Y; Yamashita N; Kitao H; Tanaka K; Saeki H; Oki E; Oda Y; Tokunaga E; Maehara Y
Clin Breast Cancer; 2018 Aug; 18(4):e643-e650. PubMed ID: 29275106
[TBL] [Abstract][Full Text] [Related]
14. Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint.
Kleiblova P; Shaltiel IA; Benada J; Ševčík J; Pecháčková S; Pohlreich P; Voest EE; Dundr P; Bartek J; Kleibl Z; Medema RH; Macurek L
J Cell Biol; 2013 May; 201(4):511-21. PubMed ID: 23649806
[TBL] [Abstract][Full Text] [Related]
15. WIP1 phosphatase suppresses the DNA damage response during G2/prophase arrest in mouse oocytes.
Leem J; Kim JS; Oh JS
Biol Reprod; 2018 Oct; 99(4):798-805. PubMed ID: 29733326
[TBL] [Abstract][Full Text] [Related]
16. Chemical Features Important for Activity in a Class of Inhibitors Targeting the Wip1 Flap Subdomain.
Tagad HD; Debnath S; Clausse V; Saha M; Mazur SJ; Appella E; Appella DH
ChemMedChem; 2018 May; 13(9):894-901. PubMed ID: 29476592
[TBL] [Abstract][Full Text] [Related]
17. ROLE OF Wip1-p53 AXIS IN RESPONSE OF MURINE CELLS TO TREATMENT WITH SODIUM BUTYRATE AND MEK/ERK SIGNALLING PATHWAY INHIBITOR.
Kochetkova EA; Demidov ON
Tsitologiia; 2017; 59(4):285-9. PubMed ID: 30188093
[TBL] [Abstract][Full Text] [Related]
18. Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents.
Goloudina AR; Tanoue K; Hammann A; Fourmaux E; Le Guezennec X; Bulavin DV; Mazur SJ; Appella E; Garrido C; Demidov ON
Proc Natl Acad Sci U S A; 2012 Jan; 109(2):E68-75. PubMed ID: 22065775
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of Wip1 phosphatase modulates the cellular threshold of DNA damage signaling in mitosis.
Macurek L; Benada J; Müllers E; Halim VA; Krejčíková K; Burdová K; Pecháčková S; Hodný Z; Lindqvist A; Medema RH; Bartek J
Cell Cycle; 2013 Jan; 12(2):251-62. PubMed ID: 23255129
[TBL] [Abstract][Full Text] [Related]
20. Wip1 phosphatase in breast cancer.
Emelyanov A; Bulavin DV
Oncogene; 2015 Aug; 34(34):4429-38. PubMed ID: 25381821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
